Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5896
    -0.0010 (-0.17%)
     
  • NZD/EUR

    0.5529
    -0.0015 (-0.28%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.06
    +0.33 (+0.40%)
     
  • GOLD

    2,408.50
    +10.50 (+0.44%)
     
  • NASDAQ

    17,163.45
    -230.87 (-1.33%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,949.21
    +173.83 (+0.46%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    91.1010
    -0.1530 (-0.17%)
     

3 Clinical Trials to Watch in the First Half of 2022

In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.